"Committed to serving the underserved, with persistence fueled by curiosity."
I joined Genentech as a Scientist/Pathologist in 2007, following seven years at a smaller biotechnology company. I am currently a Staff Scientist/Pathologist in Safety Assessment, supporting several programs from discovery through post-marketing as a team member or leader. Within Safety Assessment, I also lead strategic support of reproductive, developmental and juvenile toxicity across our portfolio, and contribute to strategies in other areas such as safety pharmacology and inhalation toxicology. My broad interests have allowed me to build a strong foundation around drug development and its regulation and implementation. I support and applaud efforts by Roche/Genentech to uphold high standards of science, sustainability, and commitment to the ethics and welfare in support of our medical advances.
Over my career thus far, I have been able to support programs intended for diseases across a broad range of therapeutic areas including immunology, oncology, infectious diseases, and metabolism, as a team member or leader. Over the past decade especially, I have increased my knowledge and contributions in specific areas of cardiovascular safety pharmacology, developmental and reproductive toxicology (DART) and support of pediatrics. In addition to roles on internal expert working groups, I have served on a number of efforts with external organizations such as the Biotechnology Industry Organization (BioSafe Leadership Committee and representative on ICH S11), the HESI DART technical committee, the Society of Toxicologic Pathology Scientific and Regulatory Policy Committee, and the American College of Veterinary Pathology Advocacy and Policy Committee. I am also a member of the Society for Birth Defects Research and Prevention and of the Safety Pharmacology Society. I have been a Diplomate of the American College of Veterinary Pathologists since 2002.